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The radish-like hypocotyls of Maca (Lepidium meyenii Walp., Brassicaceae) are widely consumed as common 
vegetable in the Andean highlands. It is considered as healthy food, rich in carbohydrates and protein, a herbal 
medicine with a general invigorating reputation and fertility and sexual performance enhancer. The latter is the most 
popular contemporary application of the plant in Europe. The number and variety of industrial products on the 
market is increasing. Here we report the development of a simple and reliable analytical protocol for the qualitative 
and quantitative analysis of maca content of preparations and for the detection of synthetic phosphodiesterase 
inhibitors. Fourteen products were analysed by the method based on TLC and HPLC-DAD analysis developed by 
us. Our experiments revealed that beside good-quality products, the majority of the multicomponent preparations 
did not contain the declared herbal component or the quantity of the measured macamide was very low. Furthermore, 
one preparation is adulterated with a synthetic phosphodiesterase inhibitor. The presented method is suitable for 
quality control of L. meyenii products.
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Maca or Peruvian cress (Lepidium meyenii Walp.) belonging to the family of Brassicaceae, is 
a plant mainly domesticated in the Andes of Peru and Bolivia at elevations of 3500–4000 m 
above sea level. The radish-like hypocotyls are traditionally consumed by Andean native 
people as common vegetable for thousands of years (QUIRÓS & ALIAGA, 1997). In the Peruvian 
Central Andes, the average daily dose is about 20 g (GONZALES, 2012). Nowadays a variety of 
products can be found in the Peruvian markets, such as refreshing or alcoholic drinks, jams, 
or the hypocotyl powder with the purpose of making cakes or bread (QUIRÓS & ALIAGA, 1997; 
VALENTOVÁ & ULRICHOVÁ, 2003).
The plant has a multiplicity of other uses: it is widely applied as general invigorator, 
fertility enhancer for people and domesticated animals, and an ingredient of ceremonial 
concoctions (QUIRÓS & ALIAGA, 1997; WANG et al., 2007; GONZALES, 2012).
Maca has been found to contain an array of metabolites, some well-known for the 
Brassicaceae family (e.g. glucosinolates and its derivatives), others being more characteristic 
to the genus. Typical markers of the plant are the macamides, which have not been detected 
in other species. To date, 19 macamides have been described from L. meyenii (WU et al., 
2013). Depending on the origin and colour type of the hypocotyl, the composition and 
quantity of the secondary metabolites of maca may be very different (GONZALES, 2012). 
According to our actual knowledge on the chemistry of L. meyenii, macamides, alkaloids, 
glucosinolates and their derivatives, polyphenols, and fl avonoids may also take part in the 
pharmacological activity of the species. For the different colour types macaene, macamides 
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and glucosinolates differ mainly. Black and lead coloured maca contain the largest quantity 
of glucosinolates, while yellow maca is the richest in macanenes, macamides, and phenols 
(CLÉMENT et al., 2010).
Outside its native distributional range, maca is usually consumed as food supplement. 
These products contain the extract or the powdered hypocotyl of the plant. Sexual performance 
and fertility enhancement are the most popular contemporary applications of the plant in 
Europe. However, there are several preparations claimed to increase mental and physical 
performances, too. The number and variety of industrial products (predominantly dietary 
supplements, mono- and multi-component maca preparations) on the European herbal market 
– mainly sold via the internet – is increasing. The modes of action responsible for the 
supposed effects have not been fully elucidated so far. In some pharmacological experiments, 
the sexual behaviour of male rats and the erectile function of castrated rats have been 
enhanced (ZHENG et al., 2000; CICERO et al., 2001). In a similar experiment maca was inactive, 
but the cause of this could be the much lower dosage (LENTZ et al., 2007). Some clinical trials 
have been shown that long-term (4–6 weeks) consumption of dry maca hypocotyl with a 
1.5–3 g daily dosage leads to the enhancement of sexual activity and fertility of men and 
women, too (BROOKS et al., 2008; SHIN et al., 2010; GONZALES, 2012). However, these studies 
were too heterogeneous and the number of the participants too low to make a fi rm conclusion.
Since the male sexual performance enhancer effect of the plant and its metabolites has 
not been confi rmed convincingly preclinically or clinically, maca products marketed for this 
purpose are candidates for quality control focusing on activity-potentiating synthetic 
compounds to the products. Although there are data published on the maca content of several 
dietary supplements (GANZERA et al., 2002), there is a lack of studies aiming both the analysis 
of macamide content and the potential synthetic adulterants of the products. The aim of our 
work was to develop an analytical protocol for the qualitative and quantitative analysis of 
maca content of food supplements and to screen selected products for the presence of 
synthetic phosphodiesterase inhibitors.
1. Materials and methods
1.1. Chemicals and reagents
The macamide N-benzyl-(9Z,12Z)-octadecadienamide (Fig. 1) previously reported only from 
L. meyenii (MCCOLLOM et al., 2005) was isolated in our laboratory (=MACA–3) from dry 
L. meyenii hypocotyl powder (Raw Organic Maca Powder, EverTrust Ltd, UK, originating 
from Peru) using chromatographic methods. The structure of this compound was elucidated 
by 1H and 13C NMR experiments. Peak purity analysis carried out with the Empower Pro 
software confi rmed that the chromatographic peak of the compound is spectrally pure. 
Acetonitrile (LiChrosolv® HPLC grade) was obtained from Merck (Darmstadt, Germany). 
Millipore Direct-Q UV3 clarifi er (Millipore Corporation, Billerica, MA, USA) was used to 
produce purifi ed water for HPLC measurements. Synthetic phosphodiesterase inhibitors 
were isolated from medicaments (sildenafi l (Viagra), tadalafi l (Cialis), vardenafi l (Levitra)); 
their derivatives (pseudovardenafi l, nor-acetildenafi l, thiosildenafi l, dimethyl-thiosildenafi l, 
and aminotadalafi l) were isolated previously from adulterated dietary supplements. Ten 
maca-containing dietary supplements were purchased in Hungarian shops, 3 maca powders 
were provided by Ashaninka Pharma Ltd. (Hungary), 1 maca powder was purchased in a 
webshop (UK).
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1.2. Sample preparation for validation and product analysis
Dry maca hypocotyl powder (Raw Organic Maca Powder, EverTrust Ltd, UK, originating 
from Peru) was used for validation of the analytical method. Five hundred milligrams of the 
product was extracted with 10 ml n-hexane (10 min extraction in ultrasonic bath at room 
temperature), then diluted with n-hexane to 25.0 ml in a volumetric fl ask, and centrifuged (10 
min, 2500 r.p.m.). Then 20.0 ml of the supernatant were pipetted to a round-bottom fl ask and 
evaporated under vacuum. Extracts were redissolved in 2 ml n-hexane, fi ltered through a 
fi lter membrane (Acrodisc® GHP 13 mm, 0.45 μm, Waters, USA). The fi rst 0.5 ml was 
dismissed; the other 1.5 ml was analysed by HPLC-DAD. Three extracts were prepared and 
injected in triplicate.
In case of product quality analysis, 500 mg of the powder type products and 380–1000 
mg of the multicomponent preparations (depending on the tablet or capsule sizes) were 
processed as described above.
1.3. Calibration and linearity
As calibration standard N-benzyl-(9Z,12Z)-octadecadienamide (MACA–3), a major alkamide 
of L. meyenii, was applied. In order to obtain the linear range of quantifi cation, stock standard 
solution (1.2 mg ml−1) was prepared with n-hexane. Of the stock standard solution, 1.0 ml 
was transferred to 10.0 ml volumetric fl ask and diluted with n-hexane. Different amounts of 
this solution were diluted with n-hexane to obtain six different concentrations between 
0.0048–0.06 mg ml−1. The calibration range of N-benzyl-(9Z,12Z)-octadecadienamide was 
0.048–12.0 μg/injection. Ten microlitres of the standards were injected in triplicate. The 
slope, intercept, and the correlation coeffi cient were determined. For calculation of the 
calibration curve, peak areas were plotted against the injected mass of the macamide standard.
1.4. HPLC apparatus and measurement conditions
HPLC analysis was carried out on a Waters 600 system (Waters Corporation, Milford, USA), 
equipped with a 2998 photodiode array detector, on-line degasser, column thermostat, and 
autosampler using a reversed phase Kinetex XBC18 (2.6 μm, 100 Å, 100×4.6 mm column 
(Phenomenex, Torrance, USA) at 25 °C). Chromatographic elution of the samples was 
accomplished by an isocratic solvent system consisting of acetonitrile – H2O 85:15 with a 
fl ow rate of 0.7 ml min–1. For analysis, 10.0 μl extract was injected. The samples were 
monitored at 210 nm. Data acquisition and evaluation were performed using Empower Pro 
software.
1.5. Method validation
Repeatability was evaluated based on experiments with Raw Organic Maca Powder extracts. 
Intraday precisions were calculated from data acquired during a 3-day validation. Precision 
was expressed as relative standard deviation (RSD%). Signal to noise ratio was used to 
express the limit of detection (three times the noise) and quantitation (ten times the noise). 
Recovery analysis was carried out by adding known amounts of macamide (64, 128, and 
256% of N-benzyl-(9Z,12Z)-octadecadienamide) to the maca extract (n=3 at each 
concentration). To assess the stability of N-benzyl-(9Z,12Z)-octadecadienamide in the 
n-hexane extract, the extracts were stored at room temperature and analysed after 3 and 4 
days.
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1.6. Detection of phosphodiesterase inhibitors
For the presence of phosphodiesterase inhibitors, multicomponent preparations were analysed 
by TLC and HPLC-DAD according to a protocol developed in our laboratory (CSUPOR et al., 
2011). Briefl y, one capsule or tablet was extracted with 10 ml methanol for 10 minutes by 
ultrasonic bath at room temperature, and then fi ltered through a membrane fi lter.
Ten microlitres of the extracts were applied to silica gel stationary phase (Merck 
105553 60 20×20) and developed in toluene – acetone – ethanol – 25% NH3 70:50:10:3 in a 
developing chamber saturated with solvent vapour. The development distance was 20 cm. 
The detection was realized under UV (254 nm) and by spraying the plate with Dragendorff’s 
reagent or vanillin-sulphuric acid and heating at 120 °C. This method allows the identifi cation 
of phosphodiesterase inhibitors by comparing their retention factors and the colours of the 
spots to those of analytical standards. Selective detection carried out with Dragendorff’s 
reagent makes it possible to detect so far unidentifi ed synthetic derivatives.
For HPLC-DAD analysis a Gemini-NX 5u C18 100A, 100×4.6 mm column was used. 
The solvent system was NH4HCO3 (10 mM pH=10.00±0.2) – acetonitrile 7:3 with a fl ow rate 
of 1 ml min–1. Twenty millilitres of extract was injected. The samples were monitored in the 
whole UV range (200–400 nm) and at 220, 254, 282, and 292 nm. Data acquisition and 
evaluation were performed using Empower Pro software. Synthetic phosphodiesterase 
inhibitors can be identifi ed based on their retention times and characteristic UV spectra.
2. Results and discussion
2.1. Method validation
Linear calibration curve (y=1871×710.20x+3015.43) was established with a correlation 
coeffi cient (R2) of 1.00, which allows reliable quantifi cation. N-Benzyl-(9Z,12Z)-
octadecadienamide content of 6 preparations was below the limit of detection and above the 
limit of quantifi cation in case of 8 products. The intraday precision, obtained during the 
validation for N-benzyl-(9Z,12Z)-octadecadienamide, ranged between 0.80 and 1.11%. 
These results underline the good repeatability of our method. The recovery was 97% (RSD% 
0.80) for the fi rst concentration, 99.6% (RSD% 2.90) and 98.8% (RSD%) for the second and 
third concentrations, respectively. These results are in accordance with recovery values of 
previously published methods (GANZERA et al., 2002; MCCOLLOM et al., 2005) and confi rm the 
good accuracy of our method. According to the stability measurements, the N-benzyl-
(9Z,12Z)-octadecadienamide content of n-hexane extracts stored for 3 and 4 days at room 
temperature were 96.53% and 103.40%, respectively, of the original samples. These results 
indicate that the decomposition of this macamide is not signifi cant and therefore analysis can 
be carried out reliable from fresh samples.
2.2. Product analysis
Fourteen maca products containing mono- (5) and multicomponent (9) preparations 
(distributed by 11 companies) were randomly selected and purchased (Table 1). The origin of 
the monocomponent products was Peru, the multicomponent preparations derived from 
China (5), UK (2), and other EU countries (2). Their pharmaceutical form was powder (4), 
capsule (6), tablet (2), ampoule (1), and spray (1). In case of monocomponent preparations 
(1–5 products) the recommended daily posologies (1500–5000 mg dry hypocotyl powder) 
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overlap with the effective dosages used in human studies (QUIRÓS & ALIAGA, 1997; WANG et 
al., 2007; GONZALES, 2012), but for multicomponent products (6–14.) are much lower, 
between 80–125 mg for 4 products, 500 and 750 mg in two cases, and not declared in one 
case. However, 4 products (6, 8, 12, and 13) were claimed to contain “maca extract” 
(unspecifi ed), in 1 case dry hypocotyl powder (11), and in 4 cases (7, 9, 10, and 14) no further 
information was given. The most preferred recommendations for the products were “potency 
enhancer”, “for men”, “for the reproductive system”, and “mental and physical capacity 
enhancer”. Among thirty other herbal (28), animal (2), or fungal (1) ingredients the most 
preferred ones were Serenoa repens (labelled in 7 products), Panax ginseng (5), Ginkgo 
biloba (4), Rhodiola rosea (3), and Urtica dioica (3). The majority of these are widely used 
either for symptoms of the genitourinary system or as physical or sexual performance 
enhancer.






(μg 1-1 g 
product)




Raw Organic Maca Powder 
(yellow coloured)
powder1 3–5 g 193.1 579.3–955.5 
2. (Peru)
Red Maca Powder
powder1 no data 225.8
3. (Peru)
Black Maca Powder
powder1 no data 63.0
4. (Peru)
Gelatinazed Maca Powder
powder1 no data 28.0
5. (Peru) tablet1 1500 mg 45.2 67.8
6. (EU) capsule2 one capsule 30.9 15.45
7. (UK) capsule2 one capsule per day for 5 
days, then 2 days break
2.6 1.3
8. (China) tablet2 one–two tablets per day, 
for 4–6 weeks
13.9 13.9–27.8
9. (China) capsule2 maximum one capsule in 
every three days
n.d. Presence of thiosildenafi l
10. (China) capsule2 one–two capsules 30 
minutes before the sexual 
activity
n.d.
11. (EU) capsule2 two capsules before sexual 
activity
n.d.
12. (China) capsule2 one–two capsules one hour 
before sexual activity
n.d.
13. (China) ampule2 one ampule n.d.
14. (UK) spray2 3–5 puffs locally n.d.
1: monocomponent preparations; 2: multicomponent preparations, n.d.: not detected
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The HPLC method developed by us allowed the reliable analysis of one of the major 
macamides of L. meyenii. The good separation of N-benzyl-(9Z,12Z)-octadecadienamide 
from other components of the extracts provided robustness for the method. HPLC-DAD 
analysis revealed that signifi cant peaks with higher retention times than that of this compound 
do not belong to the class of macamides. From the 14 analysed preparations, the presence of 
maca was confi rmed in 8 products. The HPLC-UV chromatograms (210 nm) of maca 
containing products were similar to that of Raw Organic Maca Powder (Fig. 1).
Fig. 1. HPLC-UV chromatogram of a maca extract (210 nm) and the structure 
of N-benzyl-(9Z,12Z)-octadecadienamide (MACA-3)
In the maca powders 28.0–225.8 μg N-benzyl-(9Z,12Z)-octadecadienamide/g was 
present. Marked differences in macamide content could be detected in case of the different 
colour types. In 6 preparations the concentration of the marker macamide was below the 
detection limit and one preparation was adulterated with a synthetic phosphodiesterase 
inhibitor. Thiosildenafi l, a derivative of sildenafi l has been detected by TLC and HPLC-DAD 
(retention time 7.2 min, maximal UV absorption at 282 nm) in this product.
3. Conclusions
Increased use of dietary supplements is a worldwide phenomenon. The public opinion that 
these products are natural and hence safe plays important role in their increased commerce. 
The way and goals of application of maca in Europe is largely different from the traditional 
use. Due to the lack of proper quality control in some cases the declared and the real 
compositions of the products are different and certain products contain non-labelled 
substances, including synthetic compounds, to enhance the effect.
In half of the 14 randomly selected maca products the maca content could be detected 
by our method, however, in 6 food supplements the concentration of the marker macamide 
was below the detection limit and one of the products was adulterated with a synthetic 
compound. The calculated maca content in the recommended daily doses of the majority of 
products were below the widely accepted posology of the plant. Our results draw attention to 
the need for proper quality control of maca-containing dietary supplements.
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